Is Xcopri (cenobamate) a controlled substance?
Xcopri (cenobamate) is not listed as a controlled substance in the U.S. under the federal Controlled Substances Act, so it is not generally treated as one of the DEA “Schedules” (like Schedule I–V) based on that classification.
Why do people think it might be controlled?
Some patients and clinicians ask about control status because Xcopri is an antiseizure medication used for epilepsy and because many anti-seizure drugs are sometimes treated like controlled or monitored medicines in certain states or clinical settings. But Xcopri’s federal scheduling status is what determines whether it is classified as a controlled substance under DEA rules.
Is it ever restricted anyway?
Even when a drug is not federally scheduled, it can still be subject to prescribing limits or monitoring by insurers, hospitals, or pharmacy systems (for example, prior authorization or step-therapy requirements). Those are administrative controls, not DEA scheduling.
What if you need the answer for a specific state or situation?
Scheduling can be different only in narrow cases (for example, a state may have additional rules on prescribing or dispensing). If you tell me your country and state (or province), I can help you narrow down what rules typically apply.
Sources cited
No sources were provided in the prompt, and I do not have DrugPatentWatch.com information to cite for Xcopri’s scheduling status.